About Concert Pharmaceuticals, Inc. (CNCE) — Dividend Analysis 2026
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Is CNCE a good dividend investment in 2026?
CNCE offers a 23.89% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
CNCE DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your CNCE portfolio grows to $12.89M vs $10.26M without reinvestment. This is the compound interest effect in action.
CNCE dividend growth history & forecast
CNCE has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 23.89%.
Company generates negative FCF ($-55M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.1B → -0.1B → -0.1B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 CNCE Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CNCE.
Gross yield
23.89%
Tax rate
15.00%
After-tax yield
20.31%
Real yield (−CPI)
17.51%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
23.89%
21.09%
$2,389 / yr
🇺🇸 US Taxable (15%) ✓
15%
20.31%
17.51%
$2,031 / yr
🇺🇸 US Taxable (20%)
20%
19.11%
16.31%
$1,911 / yr
🇬🇧 UK ISA
0%
23.89%
21.09%
$2,389 / yr
🇬🇧 UK Taxable
8.75%
21.80%
19.00%
$2,180 / yr
🇨🇦 TFSA
0%
23.89%
21.09%
$2,389 / yr
🇨🇦 CA Taxable
25%
17.92%
15.12%
$1,792 / yr
🇦🇺 Super (pension)
15%
20.31%
17.51%
$2,031 / yr
🇦🇺 AU Taxable
30%
16.72%
13.92%
$1,672 / yr
🇩🇪 DE Taxable
26.375%
17.59%
14.79%
$1,759 / yr
🇫🇷 FR Taxable
30%
16.72%
13.92%
$1,672 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CNCE Income Goal & Break-Even
Dividend Break-Even
5yr
Years for dividends to fully repay your CNCE investment of $8.37/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$23.8K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$21.3K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in CNCE for:
Shares needed
14,118
Capital required
$118,168
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CNCE Dividend Payment Schedule
CNCE pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 CNCE vs Healthcare Benchmarks
How CNCE compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+21.09% vs sectorBetter
CNCE
23.89%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
CNCE
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
CNCE
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CNCE sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CNCE Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
van Heek Christi
director
U-Tender
2023-03-06
25,651
$8.00
$205.2K
van Heek Christi
director
D-Return
2023-03-06
14,144
$9.16
$129.6K
van Heek Christi
director
D-Return
2023-03-06
16,400
—
—
van Heek Christi
director
D-Return
2023-03-06
25,000
$12.96
$324.0K
van Heek Christi
director
D-Return
2023-03-06
10,250
$4.26
$43.7K
van Heek Christi
director
D-Return
2023-03-06
10,000
$19.59
$195.9K
van Heek Christi
director
D-Return
2023-03-06
7,003
$5.00
$35.0K
van Heek Christi
director
D-Return
2023-03-06
10,000
$11.02
$110.2K
van Heek Christi
director
D-Return
2023-03-06
10,000
$13.29
$132.9K
Tung Roger D
director, officer: Chief Executive Officer
D-Return
2023-03-06
170,000
$16.85
$2.86M
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🔬
Financial Health Scores
Altman Z-Score
2.43
⚠️ Grey Zone — monitor closely
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
1/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CNCE dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →